Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Código da empresaSTTK
Nome da EmpresaShattuck Labs Inc
Data de listagemOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Número de funcionários44
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 09
Endereço500 W. 5Th Street
CidadeAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78701
Telefone15129004690
Sitehttps://www.shattucklabs.com/
Código da empresaSTTK
Data de listagemOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados